Endocrine diseases of any type — not just diabetes — can represent a cardiovascular risk and patients with those disorders should be screened for high cholesterol, according to a new clinical practice guideline from the Endocrine Society.
“The simple recommendation to check a lipid panel in patients with endocrine diseases and calculate cardiovascular risk may be practice changing because that is not done routinely,” Connie Newman, MD, chair of the Endocrine Society committee that developed the guideline, told Medscape Medical News.
“Usually the focus is on assessment and treatment of the endocrine disease, rather than on assessment and treatment of atherosclerotic cardiovascular disease risk,” said Newman, an adjunct professor of medicine in the Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, at the New York University Grossman School of Medicine in New York City.
Whereas diabetes, well-known for its increased cardiovascular risk profile, is commonly addressed in other cardiovascular and cholesterol practice management guidelines, the array of other endocrine diseases are not typically included.
“This guideline is the first of its kind,” Newman said.
“The Endocrine Society has not previously issued a guideline on lipid management in endocrine disorders (and) other organizations have not written guidelines on this topic.”
“Rather, guidelines have been written on cholesterol management, but these do not describe cholesterol management in patients with endocrine diseases such as thyroid disease (hypothyroidism and hyperthyroidism), Cushing’s syndrome, acromegaly, growth hormone deficiency, menopause, male hypogonadism, and obesity,” she noted.
But these conditions carry a host of cardiovascular risk factors that may require careful monitoring and management.
“Although endocrine hormones, such as thyroid hormone, cortisol, estrogen, testosterone, growth hormone, and insulin, affect pathways for lipid metabolism, physicians lack guidance on lipid abnormalities, cardiovascular risk, and treatment to reduce lipids and cardiovascular risk in patients with endocrine diseases,” she explained.
Vinaya Simha, MD, an internal medicine specialist at the Mayo Clinic, in Rochester, Minnesota, agrees that the guideline is notable in addressing an unmet need.
Recommendations that stand out to Simha include the suggestion of adding eicosapentaenoic acid (EPA) ethyl ester to reduce the risk of cardiovascular disease in adults with diabetes or atherosclerotic cardiovascular disease who have elevated triglyceride levels despite statin treatment.
James L. Rosenzweig, MD, an endocrinologist at Hebrew SeniorLife, in Boston, Massachusetts, agrees this is an important addition to an area that needs more guidance.
“Many of these clinical situations can exacerbate dyslipidemia and some also increase the cardiovascular risk to a greater extent in combination with elevated cholesterol and/or triglycerides,” he told Medscape Medical News.
“In many cases, treatment of the underlying disorder appropriately can have an important impact in resolving the lipid disorder. In others, more aggressive pharmacological treatment is indicated,” he said.
“I think that this will be a valuable resource, especially for endocrinologists, but it can be used as well by providers in other disciplines.”
Key Recommendations for Different Endocrine Conditions
The guideline, published in the Journal of Clinical Endocrinology & Metabolism, details those risks and provides evidence-based recommendations on their